On Thursday, Starbucks (SBUX) rose 4.97 percent to $105.39. The specialty coffee maker was pleasantly delighted by its long-term projections on Thursday, expecting consumers to return after the pandemic has ended, including without seating in its new cafes.
The Walt Disney Company (DIS) rose 0.17 percent to $154.69 on the day. The entertainment giant conducted a virtual investor day. According to the New York Times, the group will announce that some of its films, including ‘Pinocchio’, will be released directly on the Disney streaming video platform.
On the other hand on Thursday, Facebook (FB) fell -0.29 percent to $277.12. The social networking giant is being sued by the Federal Trade Commission (FTC) and a bipartisan coalition of Attorney General from many states, who claim the corporation engaged in inappropriate antitrust activity by purchasing or banning new technology companies that might have been rivals. The purchase of Instagram in 2012 and WhatsApp two years later are included in this alleged ‘systemic’ anti-competitive policy. An injunction is being requested by the FTC to disinvest Facebook in these assets. The social media giant, on the other hand, claims that it was responsible for the accession to the ranks of leaders of these startups.
AT&T (T) also dropped -2.45 percent to $30.69 in Thursday session. The U.S. telecommunications giant, on Thursday announced the $1.175 billion sale of the animation company Crunchyroll to the Japanese group Sony.
Alphabet (GOOGL) was -0.57% to $1767.65 and Amazon (AMZN) almost stable (-0.09 percent) at $3101.49. For breaches of French cookie rules, the French National Commission for Information Technology and Freedoms (CNIL) has declared penalties of EUR 100 million for Google and EUR 35 million for Amazon. For these digital giants, however the sums involved are very negligible.
However, the vaccine maker Moderna (MRNA) plummeted -0.57 percent in Thursday trading to conclude at $155.69. The biotechnology company started testing adolescents aged 12 to 17 with its Covid-19 vaccine. On Thursday, the Director General of the EMA found the data submitted to the European Medicines Agency by Pfizer/BioNTech and Moderna for their vaccine candidates to be very good.